Nasdaq · CIK 0001652130
NTLA Intellia Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 6 d ago. Close $13.07 on Oct 9, 2026, +63% from the 52-week low and -53% from the high.
Last 90 days
Net insider value
-$23k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$23k by 1 insider
Insiders on file
16
with a Form 4 at this company
Price and insider trades, last year
NTLAOct 9, 2026 · close 13.07
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Intellia Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Michael P Dube VP, Chief Accounting Officer sell | $23k 1,864 shares | -3% | +52% from low-56% from high | |
| 21Weak | Michael P Dube VP, Chief Accounting Officer sell | $33k 1,871 shares | -3% | +199% from low-11% from high | |
| 58Moderate | William J Chase director buy | $1.0M 100,000 shares | +288% | +63% from low-55% from high | |
| 32Weak | Edward J Dulac III EVP, Chief Financial Officer sell | $105k 7,462 shares | -7% | +127% from low-38% from high | |
| 30Weak | Eliana Clark EVP, Chief Technical Officer sell | $10k 1,022 shares | -1% | +57% from low-57% from high | |
| 30Weak | Michael P Dube VP, Chief Accounting Officer sell | $25k 2,503 shares | -4% | +71% from low-53% from high | |
| 20Weak | Jesse Goodman director sell | $29k 3,094 shares | -11% | +49% from low-59% from high | |
| 0Weak | Muna Bhanji director sell | $2,253 265 shares | -1% | +31% from low-64% from high | |
| 23Weak | James Basta EVP, General Counsel sell | $23k 2,572 shares | -2% | - | |
| 23Weak | Eliana Clark EVP, Chief Technical Officer sell | $6,104 679 shares | -1% | - | |
| 0Weak | Muna Bhanji director sell | $2,642 265 shares | -1% | - | |
| 39Weak | James Basta EVP, General Counsel sell | $86k 7,074 shares | -9% | - | |
| 30Weak | Michael P Dube VP, Chief Accounting Officer sell | $17k 1,372 shares | -3% | - | |
| 39Weak | Derek Hicks EVP, Chief Business Officer sell | $79k 6,502 shares | -10% | - | |
| 45Moderate | Laura Sepp-Lorenzino EVP, Chief Scientific Officer sell | $109k 8,966 shares | -10% | - | |
| 55Moderate | John M Leonard President and CEO sell | $327k 26,807 shares | -3% | - | |
| 40Moderate | David Lebwohl EVP, Chief Medical Officer sell | $116k 9,557 shares | -10% | - | |
| 45Moderate | Eliana Clark EVP, Chief Technical Officer sell | $97k 7,978 shares | -11% | - |
Transactions
The last 53 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Michael P Dube VP, Chief Accounting Officer | SOpen-market sale Common Stock | -1,864 | $12.43 | $23k | 65,022 | 6 d ago |
| Oct 1, 2025 | Michael P Dube VP, Chief Accounting Officer | SOpen-market sale Common Stock | -1,871 | $17.38 | $33k | 55,266 | Oct 3, 2025 |
| Aug 20, 2025 | William J Chase director | POpen-market purchase Common Stock | +100,000 | $10.03 | $1.0M | 134,693 | Aug 22, 2025 |
| Jul 23, 2025 | Edward J Dulac III EVP, Chief Financial Officer | SOpen-market sale Common Stock | -7,462 | $14.02 | $105k | 106,062 | Jul 25, 2025 |
| Jul 2, 2025 | Michael P Dube VP, Chief Accounting Officer | SOpen-market sale Common Stock | -2,503 | $9.95 | $25k | 57,137 | Jul 3, 2025 |
| Jul 1, 2025 | Eliana Clark EVP, Chief Technical Officer | SOpen-market sale Common Stock | -1,022 | $9.82 | $10k | 95,369 | Jul 3, 2025 |
| Jun 30, 2025 | Jesse Goodman director | SOpen-market sale Common Stock10b5-1 | -1,547 | $9.56 | $15k | 25,906 | Jul 2, 2025 |
| Jul 1, 2025 | Jesse Goodman director | SOpen-market sale Common Stock10b5-1 | -1,547 | $9.23 | $14k | 24,359 | Jul 2, 2025 |
| Jun 11, 2025 | Georgia Keresty director | AGrant or award Common Stock | +8,000 | $0.00 | $0 | 31,883 | Jun 18, 2025 |
| Jun 11, 2025 | Georgia Keresty director | AGrant or award Stock Option (right to buy)derivative | +11,450 | $0.00 | $0 | 11,450 | Jun 18, 2025 |
| Jun 11, 2025 | Frank Verwiel director | AGrant or award Common Stock | +8,000 | $0.00 | $0 | 25,948 | Jun 13, 2025 |
| Jun 11, 2025 | Brian Goff director | AGrant or award Common Stock | +8,000 | $0.00 | $0 | 23,409 | Jun 13, 2025 |
| Jun 11, 2025 | Jesse Goodman director | AGrant or award Common Stock | +8,000 | $0.00 | $0 | 27,453 | Jun 13, 2025 |
| Jun 11, 2025 | Fred E Cohen director | AGrant or award Common Stock | +8,000 | $0.00 | $0 | 57,453 | Jun 13, 2025 |
| Jun 11, 2025 | William J Chase director | AGrant or award Common Stock | +8,000 | $0.00 | $0 | 34,693 | Jun 13, 2025 |
| Jun 11, 2025 | Muna Bhanji director | AGrant or award Common Stock | +8,000 | $0.00 | $0 | 27,203 | Jun 13, 2025 |
| Jun 11, 2025 | Jesse Goodman director | AGrant or award Stock Option (right to buy)derivative | +11,450 | $0.00 | $0 | 11,450 | Jun 13, 2025 |
| Jun 11, 2025 | William J Chase director | AGrant or award Stock Option (right to buy)derivative | +11,450 | $0.00 | $0 | 11,450 | Jun 13, 2025 |
| Jun 11, 2025 | Brian Goff director | AGrant or award Stock Option (right to buy)derivative | +11,450 | $0.00 | $0 | 11,450 | Jun 13, 2025 |
| Jun 11, 2025 | Fred E Cohen director | AGrant or award Stock Option (right to buy)derivative | +11,450 | $0.00 | $0 | 11,450 | Jun 13, 2025 |
| Jun 11, 2025 | Frank Verwiel director | AGrant or award Stock Option (right to buy)derivative | +11,450 | $0.00 | $0 | 11,450 | Jun 13, 2025 |
| Jun 11, 2025 | Muna Bhanji director | AGrant or award Stock Option (right to buy)derivative | +11,450 | $0.00 | $0 | 11,450 | Jun 13, 2025 |
| Apr 29, 2025 | Muna Bhanji director | SOpen-market sale Common Stock10b5-1 | -265 | $8.50 | $2,253 | 19,203 | May 1, 2025 |
| Mar 1, 2025 | John M Leonard President and CEO | AGrant or award Common Stock | +136,000 | $0.00 | $0 | 1,077,115 | Mar 4, 2025 |
| Mar 1, 2025 | David Lebwohl EVP, Chief Medical Officer | AGrant or award Common Stock | +43,200 | $0.00 | $0 | 130,866 | Mar 4, 2025 |
| Mar 1, 2025 | Birgit C Schultes EVP, Chief Scientific Officer | AGrant or award Common Stock | +37,600 | $0.00 | $0 | 105,215 | Mar 4, 2025 |
| Mar 1, 2025 | Edward J Dulac III EVP, Chief Financial Officer | AGrant or award Common Stock | +47,200 | $0.00 | $0 | 113,524 | Mar 4, 2025 |
| Mar 1, 2025 | Michael P Dube VP, Chief Accounting Officer | AGrant or award Common Stock | +14,000 | $0.00 | $0 | 59,640 | Mar 4, 2025 |
| Mar 1, 2025 | Eliana Clark EVP, Chief Technical Officer | AGrant or award Common Stock | +32,000 | $0.00 | $0 | 96,048 | Mar 4, 2025 |
| Mar 1, 2025 | James Basta EVP, General Counsel | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 114,497 | Mar 4, 2025 |
| Mar 1, 2025 | Edward J Dulac III EVP, Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +67,429 | $0.00 | $0 | 67,429 | Mar 4, 2025 |
| Mar 4, 2025 | Eliana Clark EVP, Chief Technical Officer | SOpen-market sale Common Stock | -679 | $8.99 | $6,104 | 95,369 | Mar 4, 2025 |
| Mar 1, 2025 | Birgit C Schultes EVP, Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +53,714 | $0.00 | $0 | 53,714 | Mar 4, 2025 |
| Mar 4, 2025 | James Basta EVP, General Counsel | SOpen-market sale Common Stock | -2,572 | $8.99 | $23k | 111,925 | Mar 4, 2025 |
| Mar 1, 2025 | David Lebwohl EVP, Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +61,714 | $0.00 | $0 | 61,714 | Mar 4, 2025 |
| Mar 1, 2025 | John M Leonard President and CEO | AGrant or award Stock Option (right to buy)derivative | +196,000 | $0.00 | $0 | 196,000 | Mar 4, 2025 |
| Mar 1, 2025 | James Basta EVP, General Counsel | AGrant or award Stock Option (right to buy)derivative | +57,143 | $0.00 | $0 | 57,143 | Mar 4, 2025 |
| Mar 1, 2025 | Eliana Clark EVP, Chief Technical Officer | AGrant or award Stock Option (right to buy)derivative | +45,714 | $0.00 | $0 | 45,714 | Mar 4, 2025 |
| Jan 29, 2025 | Muna Bhanji director | SOpen-market sale Common Stock10b5-1 | -265 | $9.97 | $2,642 | 19,468 | Jan 31, 2025 |
| Jan 3, 2025 | James Basta EVP, General Counsel | SOpen-market sale Common Stock | -7,074 | $12.18 | $86k | 74,497 | Jan 7, 2025 |
| Jan 3, 2025 | Michael P Dube VP, Chief Accounting Officer | SOpen-market sale Common Stock | -1,372 | $12.18 | $17k | 45,640 | Jan 7, 2025 |
| Jan 3, 2025 | Derek Hicks EVP, Chief Business Officer | SOpen-market sale Common Stock | -6,502 | $12.18 | $79k | 59,878 | Jan 7, 2025 |
| Jan 3, 2025 | Laura Sepp-Lorenzino EVP, Chief Scientific Officer | SOpen-market sale Common Stock | -8,966 | $12.18 | $109k | 77,388 | Jan 7, 2025 |
| Jan 3, 2025 | John M Leonard President and CEO | SOpen-market sale Common Stock | -26,807 | $12.18 | $327k | 941,115 | Jan 7, 2025 |
| Jan 3, 2025 | David Lebwohl EVP, Chief Medical Officer | SOpen-market sale Common Stock | -9,557 | $12.18 | $116k | 87,666 | Jan 7, 2025 |
| Jan 2, 2025 | Eliana Clark EVP, Chief Technical Officer | SOpen-market sale Common Stock | -556 | $12.03 | $6,689 | 71,470 | Jan 6, 2025 |
| Jan 3, 2025 | Eliana Clark EVP, Chief Technical Officer | SOpen-market sale Common Stock | -7,422 | $12.18 | $90k | 64,048 | Jan 6, 2025 |
| Jan 1, 2025 | Laura Sepp-Lorenzino EVP, Chief Scientific Officer | MOption exercise Common Stock | +3,500 | - | - | 86,354 | Jan 3, 2025 |
| Jan 1, 2025 | John M Leonard President and CEO | MOption exercise Common Stock | +7,850 | - | - | 967,922 | Jan 3, 2025 |
| Jan 1, 2025 | David Lebwohl EVP, Chief Medical Officer | MOption exercise Common Stock | +3,189 | - | - | 97,223 | Jan 3, 2025 |
| Jan 1, 2025 | Laura Sepp-Lorenzino EVP, Chief Scientific Officer | MOption exercise Restricted Stock Unitderivative | -3,500 | $0.00 | $0 | 0 | Jan 3, 2025 |
| Jan 1, 2025 | David Lebwohl EVP, Chief Medical Officer | MOption exercise Restricted Stock Unitderivative | -3,189 | $0.00 | $0 | 0 | Jan 3, 2025 |
| Jan 1, 2025 | John M Leonard President and CEO | MOption exercise Restricted Stock Unitderivative | -7,850 | $0.00 | $0 | 0 | Jan 3, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- James BastaEVP, General Counsel
- Muna Bhanjidirector
- William J Chasedirector
- Eliana ClarkEVP, Chief Technical Officer
- Fred E Cohendirector, owner
- Michael P DubeVP, Chief Accounting Officer
- Edward J Dulac IIIEVP, Chief Financial Officer
- Jesse Goodmandirector
- Brian Goffceo, officer, director
- Derek HicksEVP, Chief Business Officer
- Georgia Kerestydirector
- John M LeonardPresident and CEO
- David LebwohlEVP, Chief Medical Officer
- Birgit C SchultesEVP, Chief Scientific Officer
- Laura Sepp-LorenzinoEVP, Chief Scientific Officer
- Frank Verwieldirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.